Compare HRL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRL | PODD |
|---|---|---|
| Founded | 1891 | 2000 |
| Country | United States | United States |
| Employees | N/A | 5400 |
| Industry | Meat/Poultry/Fish | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.3B |
| IPO Year | 1994 | 2007 |
| Metric | HRL | PODD |
|---|---|---|
| Price | $20.36 | $154.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | $26.50 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 4.1M | 1.5M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.33 | ★ 1.30 |
| Revenue | ★ $12,106,160,000.00 | $2,708,100,000.00 |
| Revenue This Year | $2.66 | $24.55 |
| Revenue Next Year | $1.62 | $19.18 |
| P/E Ratio | ★ $61.71 | $116.99 |
| Revenue Growth | 1.55 | ★ 30.73 |
| 52 Week Low | $19.72 | $145.59 |
| 52 Week High | $31.43 | $354.88 |
| Indicator | HRL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 36.00 |
| Support Level | $20.32 | N/A |
| Resistance Level | $24.62 | $205.95 |
| Average True Range (ATR) | 0.55 | 8.17 |
| MACD | 0.01 | 0.47 |
| Stochastic Oscillator | 33.77 | 29.75 |
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.